Hoyland, it doesn't look like we are getting any data as we had hoped. Don't we deserve the biopsy data by now? It was the same old presentation, for the most part. The only working assumption is that the data has to be decent or the FDA wouldn't have them continue the trial after the first two patients. Not exactly anything to excite the retail investor, yet again.
Ann: SAN FRANCISCO BIOTECH PRESENTATION, page-3
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)